Option chain shows key data for Surrozen's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Surrozen.

Surrozen (NASDAQ:SRZN) Stock, Option Chain

Surrozen

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

May,30,,2024,,Brazil.,In,This,Photo,Illustration,,The,Worthington

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

FHTX

KSCP

PHIN

SRZN

This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Penny Stocks

Small Cap

Intraday Update

Movers

AEON

BIOR

BORR

CXAI

DOMA

DOYU

EIGR

GCTS

HGAS

HTCR

IMCC

INLX

IREN

IRON

MDIA

MESO

MMAT

NDRA

NVVE

ONDS

ORGS

OUST

PLSE

SBEV

SBFM

SGRP

SHCR

TCOM

TPET

VSTE

ZPTA

Shares of  Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.

Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

pharma lab worker ai

Biotech

Equities

Health Care

Financing

Offerings

General

Surrozen engages in a private placement, aiming to raise approximately $192.5 million in gross proceeds. Updates on SZN-043 Phase 1a trial reveal promising safety, tolerability, and effects on liver function.

Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?

Surrozen Inc

Press Releases

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Earnings

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Aligos Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Celularity

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

Forte Biosciences

iBio

MiNK Therapeutics

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Lantern Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OSR Holdings

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

Shattuck Labs

X4 Pharmaceuticals

Xilio Therapeutics

HC Wainwright & Co.

Guggenheim

B of A Securities

Comments

Surrozen

Surrozen (SRZN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga